Company intelligence / Profile preview

Expert Systems

Rockville, Maryland, United States

Ownership: Private
Development stage: Preclinical

Overview

Expert Systems has demonstrated promising Phase 1 results with its next-generation BCL2 inhibitor, lonitoclax, showing improved safety and pharmacology over existing therapies like venetoclax. The company’s AI-enabled platform accelerates drug discovery from target identification through candidate selection, supporting rapid transition from in silico design to first-in-human trials. It has managed over 30 R&D programs globally.

Therapeutic areas: Oncology
Modalities: Small moleculesBCL2 inhibitors
Industry: Biotech

Drug pipeline

1 asset

AL-0433

Preclinical

Partnerships

Lomond TherapeuticsRambam AGNLC Health VenturesEilean Therapeutics LLC

Beyond the preview

Go deeper on Expert Systems.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Expert Systems.

Explore the full profile